118 HR 3884 : Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 U.S. House of Representatives 2024-09-24 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IIB118th CONGRESS2d SessionH. R. 3884IN THE SENATE OF THE UNITED STATESSeptember 24, 2024Received; read twice and referred to the Committee on Health, Education, Labor, and PensionsAN ACTTo amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.

1.

Short title

This Act may be cited as the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023.

2.

Reauthorization of sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment

Section 1106(b) of the Public Health Service Act (42 U.S.C. 300b–5(b)) is amended—(1)in paragraph (3)(A), by inserting , grant, or cooperative agreement after contract; and (2)in paragraph (6), by striking $4,455,000 for each of fiscal years 2019 through 2023 and inserting $8,205,000 for each of fiscal years 2024 through 2028.

Passed the House of Representatives September 23, 2024.Kevin F. McCumber,Clerk.